{'52WeekChange': 0.53482926,
 'SandP52WeekChange': None,
 'address1': '770 Lindaro Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 122.96,
 'askSize': 3200,
 'averageDailyVolume10Day': 1006750,
 'averageVolume': 1558480,
 'averageVolume10days': 1006750,
 'beta': 1.088515,
 'beta3Year': None,
 'bid': 122.95,
 'bidSize': 800,
 'bookValue': 17.924,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Rafael',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 124.985,
 'dayLow': 121.63,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 244.276,
 'enterpriseToRevenue': 12.346,
 'enterpriseValue': 22288947200,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 120.410286,
 'fiftyTwoWeekHigh': 131.95,
 'fiftyTwoWeekLow': 62.88,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 179589082,
 'forwardEps': 1.43,
 'forwardPE': 85.97902,
 'fromCurrency': None,
 'fullTimeEmployees': 3001,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.00495,
 'heldPercentInstitutions': 0.99303,
 'industry': 'Biotechnology',
 'isEsgPopulated': True,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/biomarin.com',
 'longBusinessSummary': 'BioMarin Pharmaceutical Inc., a biotechnology '
                        'company, develops and commercializes therapies for '
                        'people with serious and life-threatening rare '
                        'diseases and medical conditions. Its commercial '
                        'products include Aldurazyme to treat '
                        'mucopolysaccharidosis I, a genetic disease; Brineura '
                        'for the treatment of late infantile neuronal ceroid '
                        'lipofuscinosis type 2, a form of Batten disease; and '
                        'Kuvan, a proprietary synthetic oral form of 6R-BH4 '
                        'that is used to treat patients with phenylketonuria '
                        "(PKU), an inherited metabolic disease. The company's "
                        'commercial products also comprise Naglazyme, a '
                        'recombinant form of N-acetylgalactosamine 4-sulfatase '
                        'for patients with mucopolysaccharidosis VI; Palynziq, '
                        'a PEGylated recombinant phenylalanine ammonia lyase '
                        'enzyme for adult patients with PKU; and Vimizim, an '
                        'enzyme replacement therapy for the treatment of '
                        'mucopolysaccharidosis IV Type A, a lysosomal storage '
                        'disorder. Its clinical and pre-clinical product '
                        'pipeline includes valoctocogene roxaparvovec, an '
                        'adeno associated virus vector, which is in Phase III '
                        'clinical trial for the treatment of patients with '
                        'severe hemophilia A; vosoritide, a peptide '
                        'therapeutic that is in Phase III clinical trial for '
                        'the treatment of achondroplasia, a form of '
                        'disproportionate short stature in humans; and BMN '
                        '307, an AAV5 mediated gene therapy to normalize blood '
                        'phenylalanine concentration levels in patients with '
                        'phenylketonuria. The company serves specialty '
                        'pharmacies; and end-users, such as hospitals and '
                        'foreign government agencies, as well as distributors '
                        'and pharmaceutical wholesalers in the United States, '
                        'Europe, Latin America, and internationally. BioMarin '
                        'Pharmaceutical Inc. has collaboration and license '
                        'agreements with Sarepta Therapeutics and Asubio '
                        'Pharma Co., Ltd.; and a preclinical collaboration and '
                        'license agreement with DiNAQOR AG for the development '
                        'of gene therapies to treat rare genetic '
                        'cardiomyopathies. The company was founded in 1996 and '
                        'is headquartered in San Rafael, California.',
 'longName': 'BioMarin Pharmaceutical Inc.',
 'market': 'us_market',
 'marketCap': 22233907200,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_25605',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': 114006000,
 'nextFiscalYearEnd': 1640908800,
 'open': 123.41,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 7.39,
 'phone': '415 506 6700',
 'previousClose': 124.49,
 'priceHint': 2,
 'priceToBook': 6.859518,
 'priceToSalesTrailing12Months': 12.315415,
 'profitMargins': 0.06315,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 124.985,
 'regularMarketDayLow': 121.63,
 'regularMarketOpen': 123.41,
 'regularMarketPreviousClose': 124.49,
 'regularMarketPrice': 123.41,
 'regularMarketVolume': 1180335,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 180836992,
 'sharesPercentSharesOut': 0.0583,
 'sharesShort': 10539174,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 9871336,
 'shortName': 'BioMarin Pharmaceutical Inc.',
 'shortPercentOfFloat': 0.066700004,
 'shortRatio': 6.18,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'BMRN',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': 0.635,
 'trailingPE': 193.62204,
 'twoHundredDayAverage': 97.19669,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'bcd60339-c59b-3a43-af89-b10253407aca',
 'volume': 1180335,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.biomarin.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94901'}